PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Octagon Research Solutions, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Octagon Research Solutions, Inc. Unveils ViewPoint 3.6 and Newly Designed eCTD Suite 2.0 - Octagon Research Solutions, Inc., today unveiled ViewPoint® 3.6, the latest edition of the industry’s first comprehensive Enterprise Submission Process Management Solution
Octagon Research Solutions, Inc. Unveils ViewPoint 3.6 and Newly Designed eCTD Suite 2.0

 

NewswireToday - /newswire/ - Wayne, PA, United States, 2006/06/22 - Octagon Research Solutions, Inc., today unveiled ViewPoint® 3.6, the latest edition of the industry’s first comprehensive Enterprise Submission Process Management Solution.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Octagon Research Solutions, Inc., a pioneer and leader in the electronic transformation of clinical R&D to the life sciences industry, today unveiled ViewPointâ 3.6, the latest edition of the industry’s first comprehensive Enterprise Submission Process Management Solution, for managing complex, cross-functional processes in support of regulatory submissions. In addition, the company also announced availability of the Octagon eCTD Suite, which includes Octagon’s eCTD Viewer and eCTD Validator.

Octagon’s award winning ViewPoint® solution streamlines the submission process for Pharmaceutical/Biotech organizations by providing visibility into the planning and management of the drug submission processes while allowing users to track, manage and compile any type of regulatory application.
ViewPoint 3.6 Resource Estimator, Reviewer and Regulatory Dashboard have been enhanced to provide unprecedented workflow estimation, collaboration and project tracking across the submission lifecycle.

“When utilizing the ViewPoint Regulatory Dashboard, submission managers have real-time visibility into the status of deliverables, issues, resources and milestones within submission projects,” stated Kirk Gallion, Octagon’s president, “The new web-based ViewPoint Reviewer provides content contributors with the ability to view their document in the context of a submission, this is the next generation tool that the industry needs, here today.”

As the industry continues to move toward global standards for regulatory submissions, companies must be ready for the intricacies of implementing the eCTD. Octagon’s innovative eCTD suite offers comprehensive viewing and validation capabilities, limiting the risk of missing a submission date or filing an incomplete or noncompliant eCTD submission.

Octagon’s eCTD Suite 2.0 includes the eCTD Validator, which allows users to confirm that their submissions are meeting the expectations set forth within ICH and regional specifications, guidance and industry best practices. Octagon’s eCTD Viewer provides practical viewing functionality that supports the entire eCTD submission lifecycle. Octagon’s eCTD Viewer also facilitates searches across instances and displays leaf lifecycles including leaves in related dossiers.

“Yesterday’s paper-based technologies and processes cannot deliver the efficiencies and intelligence that Pharmaceutical and Biotech companies need to make effective decisions about their submissions and execute them in real-time,” says Jim Walker, Octagon’s CEO and Chairman. “By providing solutions that offer greater clarity and control over their operations and complete support for evolving submission standards such as eCTD, we’ve transformed the complex submission process into a science.”

ViewPoint 3.6 and the Octagon eCTD Suite 2.0 will be available for demonstration at the 42nd Annual DIA (Drug Information Association) Meeting on June 18-22nd at the Philadelphia Convention Center booth number 1809.

About Octagon Research Solutions, Inc.
Octagon is a pioneer and leading process-centric solutions provider that offers a suite of regulatory, clinical, process and IT solutions to the life sciences industry. Octagon synchronizes processes and increases automation to reduce island-to-island inefficiencies within the clinical research and development process. We leverage the power of electronic submissions through cross-functional eSub expertise, a holistic process approach, deep domain knowledge and integrated solutions. Octagon is headquartered in Wayne, PA, with offices in Boston, MA, Costa Mesa, CA, and European headquarters in Amersham, UK.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Octagon Research Solutions, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Octagon Research Solutions, Inc. Unveils ViewPoint 3.6 and Newly Designed eCTD Suite 2.0

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Jim Graham 
610 535 6500 5655 jgraham[.]octagonresearch.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Octagon Research Solutions, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Octagon Research Solutions, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)